Physician profile
Soonduck Lee
NPI 1609396258
$4,822.07
in general payments reported to CMS, 2019-2025
20 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $246 · 2023: $1,201 · 2024: $1,154 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,010.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $1,103.31 | 2023-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novartis Pharmaceuticals Corporation | $1,011.30 | 2021-2025 | |
| Novo Nordisk INC | $453.76 | 2022-2025 | Wegovy, Ozempic |
| Amgen INC. | $380.53 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $293.94 | 2022-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $287.07 | 2021 | |
| Heartflow, INC. | $278.30 | 2025 | |
| Abbvie INC. | $224.45 | 2023-2024 | |
| Lilly USA, LLC | $211.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $111.13 | 2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $111.04 | 2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $49.90 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $48.11 | 2023-2025 | Eliquis |
| Scpharmaceuticals INC. | $46.68 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.92 | 2023-2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.60 | 2024 | Wainua, Farxiga |
| Pfizer INC. | $39.89 | 2025 | |
| Amarin Pharma, INC. | $33.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.37 | 2024 | Xarelto |
| Abbott Laboratories | $21.41 | 2023 | Mitraclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soonduck Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.